ArticlePostepy dermatologii i alergologii2025
Does IL-31 level have more significance in chronic urticaria, when compared with IL-33 level?
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic urticaria is a disease characterized by recurrent itchy wheals and/or angioedema lasting longer than 6 weeks. Its pathogenesis is multifactorial, and there are studies showing that interleukin (IL)-31 and IL-33 cytokines play a role in the pathogenesis. Material and methods: A total of 79 chronic urticaria patients aged between 18 and 65 years who applied to the allergy outpatient clinic between October and December 2020 were included in the study. While 35 patients were given antihistamine treatment alone, 44 patients were given omalizumab in addition to antihistamines. In addition to routine examination of chronic urticaria patients, serum IL-31 and IL-33 levels were studied in patients and healthy volunteers. Results: The only variable that was found to be statistically significantly higher in chronic urticaria patients compared with the control group was the IL-31 level. There was no significant difference when the groups were compared in terms of the IL-33 level. There was no significant change in IL-31 and IL-33 levels before and after treatment in patients receiving omalizumab treatment. Conclusions: IL-31 levels were found to be high in chronic urticaria patients receiving antihistamine treatment, independent of omalizumab treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.